{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:47:21Z","timestamp":1776822441744,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"DOI":"10.7759\/cureus.94023","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:00:38Z","timestamp":1759842038000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Tofacitinib in Refractory Axial Spondylarthritis: A Dose-Escalation Study"],"prefix":"10.7759","author":[{"given":"Abdul Mahin","family":"Tazbir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Abul Kalam","family":"Azad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abul Khair","family":"Ahmedullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Masudul","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahmida","family":"Nishu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Atiqur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toufiqe  E","family":"Ealahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Nazrul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun J","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al.. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011, 70:896-904. 10.1136\/ard.2011.151027","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4111-4","article-title":"Rheumatology science and practice in India","volume":"38","author":"Misra DP","year":"2018","unstructured":"Misra DP, Sharma A, Agarwal V. Rheumatology science and practice in India. Rheumatol Int. 2018, 38:1587-600. 10.1007\/s00296-018-4111-4","journal-title":"Rheumatol Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0973-3698(10)60531-6","article-title":"Indian Rheumatology Association consensus statement on the diagnosis and treatment of axial spondyloarthropathies","volume":"5","author":"Malaviya AN","year":"2010","unstructured":"Malaviya AN, Shankar S, Arya V, et al.. Indian Rheumatology Association consensus statement on the diagnosis and treatment of axial spondyloarthropathies. Indian J Rheumatol. 2010, 5:16-34. 10.1016\/S0973-3698(10)60531-6","journal-title":"Indian J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-020-00169-w","article-title":"Prevalence of musculoskeletal conditions and related disabilities in Bangladeshi adults: a cross-sectional national survey","volume":"4","author":"Zahid-Al-Quadir A","year":"2020","unstructured":"Zahid-Al-Quadir A, Zaman MM, Ahmed S, et al.. Prevalence of musculoskeletal conditions and related disabilities in Bangladeshi adults: a cross-sectional national survey. BMC Rheumatol. 2020, 4:69. 10.1186\/s41927-020-00169-w","journal-title":"BMC Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233","article-title":"Correction: the development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part ii): validation and final selection","volume":"78","author":"Rudwaleit MV","year":"2019","unstructured":"Rudwaleit MV, Van Der Heijde D, Landew\u00e9 R, et al.. Correction: the development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part ii): validation and final selection. Ann Rheum Dis. 2019, 78:e59. 10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00194-8","article-title":"Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: a systematic review","volume":"7","author":"Yi E","year":"2020","unstructured":"Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: a systematic review. Rheumatol Ther. 2020, 7:65-87. 10.1007\/s40744-020-00194-8","journal-title":"Rheumatol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.8.693","article-title":"Employment perspectives of patients with ankylosing spondylitis","volume":"61","author":"Chorus AM","year":"2002","unstructured":"Chorus AM, Boonen A, Miedema HS, van der Linden S. Employment perspectives of patients with ankylosing spondylitis. Ann Rheum Dis. 2002, 61:693-9. 10.1136\/ard.61.8.693","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170222","article-title":"Challenges and advances in targeting remission in axial spondyloarthritis","volume":"45","author":"Baraliakos X","year":"2018","unstructured":"Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, DE Vlam K. Challenges and advances in targeting remission in axial spondyloarthritis. J Rheumatol. 2018, 45:153-7. 10.3899\/jrheum.170222","journal-title":"J Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000475","article-title":"Epidemiology of axial spondyloarthritis: an update","volume":"30","author":"Wang R","year":"2018","unstructured":"Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018, 30:137-43. 10.1097\/BOR.0000000000000475","journal-title":"Curr Opin Rheumatol"},{"key":"ref10","unstructured":"Highlights of prescribing information | XELJANZ | Drugs@FDA. FDA-Approved Drugs. (2024). Accessed: October 2, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/203214s034,208246s021,213082s006lbl.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-\u03b3 and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima K","year":"2012","unstructured":"Maeshima K, Yamaoka K, Kubo S, et al.. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-\u03b3 and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012, 64:1790-8. 10.1002\/art.34329","journal-title":"Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550 in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"9","author":"Burmester GR","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al.. Tofacitinib (CP-690,550 in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013, 9:451-60. 10.1016\/S0140-6736(12)61424-X","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.77971","article-title":"Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology","volume":"56","author":"Kucharz EJ","year":"2018","unstructured":"Kucharz EJ, Stajszczyk M, Kotulska-Kucharz A, et al.. Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. Reumatologia. 2018, 56:203-11. 10.5114\/reum.2018.77971","journal-title":"Reumatologia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman D","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al.. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017, 377:1525-36. 10.1056\/NEJMoa1615977","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al.. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017, 376:1723-36. 10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"27","author":"Ruperto N","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, etal. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021, 27:1984-96. 10.1016\/S0140-6736(21)01255-1","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar A","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, et al.. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021, 80:1004-13. 10.1136\/annrheumdis-2020-219601","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03442-2","article-title":"Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis","volume":"Dec 19;26(1)","author":"Gladman DD","year":"2024","unstructured":"Gladman DD, Nash P, Mease PJ etal.. Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis. Arthritis Res Ther.  2024 , Dec 19;26(1):218. 10.1186\/s13075-024-03442-2","journal-title":"Arthritis Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13263.","article-title":"Inflammatory back pain and associated disease conditions among patients with chronic low back pain in Bangladesh","volume":"May;21(5)","author":"Yesmin S","year":"2018","unstructured":"Yesmin S, Abdal SJ, Rahman A etal . Inflammatory back pain and associated disease conditions among patients with chronic low back pain in Bangladesh.  Int J Rheum Dis. 2018, May;21(5):937-942. 10.1111\/1756-185X.13263.","journal-title":"Int J Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14008","article-title":"Development of a Bangla version of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI)","volume":"24","author":"Abdal SJ","year":"2021","unstructured":"Abdal SJ, Yesmin S, Shazzad MN, et al.. Development of a Bangla version of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI). Int J Rheum Dis. 2021, 24:74-80. 10.1111\/1756-185X.14008","journal-title":"Int J Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12032","article-title":"Cross-cultural adaptation and validation of a Bengali Health Assessment Questionnaire for use in rheumatoid arthritis patients","volume":"16","author":"Islam N","year":"2013","unstructured":"Islam N, Baron Basak T, OudeVoshaar MA, Ferdous N, Rasker JJ, Atiqul Haq S. Cross-cultural adaptation and validation of a Bengali Health Assessment Questionnaire for use in rheumatoid arthritis patients. Int J Rheum Dis. 2013, 16:413-7. 10.1111\/1756-185X.12032","journal-title":"Int J Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.05.004","article-title":"The Bengali Short Form-36 was acceptable, reliable, and valid in patients with rheumatoid arthritis","volume":"65","author":"Feroz AH","year":"2012","unstructured":"Feroz AH, Islam MN, ten Klooster PM, Hasan M, Rasker JJ, Haq SA. The Bengali Short Form-36 was acceptable, reliable, and valid in patients with rheumatoid arthritis. J Clin Epidemiol. 2012, 65:1227-35. 10.1016\/j.jclinepi.2012.05.004","journal-title":"J Clin Epidemiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"1","author":"Van der Heijde D","year":"2018","unstructured":"Van der Heijde D, Baraliakos Xetal.. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018, 1:2378-87. 10.1016\/S0140-6736(18)32463-2","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar A","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al.. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022, 400:369-79. 10.1016\/S0140-6736(22)01212-0","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01303-3","article-title":"Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis","volume":"37","author":"Pope J","year":"2020","unstructured":"Pope J, Sawant R, Tundia N, et al.. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther. 2020, 37:2356-72. 10.1007\/s12325-020-01303-3","journal-title":"Adv Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.10.003","article-title":"Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis","volume":"52","author":"Lair-Mehiri L","year":"2020","unstructured":"Lair-Mehiri L, Stefanescu C, Vaysse T, et al.. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020, 52:268-73. 10.1016\/j.dld.2019.10.003","journal-title":"Dig Liver Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-024-00402-x","article-title":"Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis","volume":"64","author":"Deodhar A","year":"2024","unstructured":"Deodhar A, Akar S, Curtis JR, et al.. Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis. Adv Rheumatol. 2024, 64:87. 10.1186\/s42358-024-00402-x","journal-title":"Adv Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens R","year":"2019","unstructured":"Westhovens R. Clinical efficacy of new JAK inhibitors under development. Just more of the same?. Rheumatology (Oxford). 2019, 58:i27-33. 10.1093\/rheumatology\/key256","journal-title":"Rheumatology (Oxford)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03313-w","article-title":"Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis","volume":"26","author":"Navarro-Comp\u00e1n V","year":"2024","unstructured":"Navarro-Comp\u00e1n V, Deodhar A, Bahiri R, Bushmakin AG, Cappelleri JC, Rammaoui J. Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis. Arthritis Res Ther. 2024, 26:105. 10.1186\/s13075-024-03313-w","journal-title":"Arthritis Res Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280672","article-title":"Prevalence and factors associated with dyslipidemia in Bangladeshi adults","volume":"18","author":"Ali N","year":"2023","unstructured":"Ali N, Samadder M, Kathak RR, Islam F. Prevalence and factors associated with dyslipidemia in Bangladeshi adults. PLoS One. 2023, 18:e0280672. 10.1371\/journal.pone.0280672","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/384554-efficacy-of-tofacitinib-in-refractory-axial-spondylarthritis-a-dose-escalation-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:00:39Z","timestamp":1759842039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/384554-efficacy-of-tofacitinib-in-refractory-axial-spondylarthritis-a-dose-escalation-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.94023","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}